Abstract 3156
Background
LAPTM5 (lysosomal-associated protein transmembrane 5) is a protein that is preferentially expressed in immune cells, and it interacts with the Nedd4 family of ubiquitin ligases. Recent studies in T and B cells identified LAPTM5 as a negative regulator of T and B cell receptor levels at the plasma membrane, but a positive modulator of inflammatory signaling pathways and hence cytokine secretion in macrophages. However, the expression and function of LAPTM5 in ovarian cancer remains undefined.
Methods
LAPTM5 expression in ovarian cancer, benign and normal ovarian tissues was examined by immunohistochemistry. The LAPTM5 mRNA and protein level of OV cells were detected by Q-PCR and Western blotting respectively. Cell apoptosis, migration and invasion changes were observed through high-content screening. The proteins expression involved in epithelial-mesenchymal transition (EMT) and TGF-β mediated signaling pathways was verified by Werstern blotting and immunofluorescence. The role of LAPTM5 on tumorigenesis in vivo was detected by the xenograft model.
Results
Our study showed that in human OV cell lines and tissues, LAPTM5 were significantly induced at both mRNA and protein levels. Furthermore, an OV cell model with downregulated LAPTM5 were established, revealing a significantly alteration of apoptosis. Moreover, analysis of the changes of migration and invasion, showed significant reduced LAPTM5 suppressed cell metastasis. Proteins involved in EMT were strongly altered, which plays a central role in cell metastasis. In addition, phosphorylated ERK1/2, p38 and JNK, key members of mitogen-activated protein kinase (MAPK) family, and phosphorylated Smad2 and Smad3 of Smad signaling pathways mediated by TGF-β regulating OV cells EMT, were strongly decreased. And, LAPTM5 knockdown also inhibited tumorigenesis in xenograft model.
Conclusions
Taken together, our results suggested that LAPTM 5 acts as a positive modulator of MAPK and TGFβ/Smad signaling pathways mediated by TGFβ in OV cells.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Beijing Obstetrics and Gynecology Hospital, Capital Medical University.
Funding
The National Natural Science Foundation of China (grants 81672838), Beijing Municipal Science & Technology Commission (No. Z181100001718193).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3061 - Poor prognostic impact of NTRK2 gene variation in Esophageal Squamous Cell Carcinoma
Presenter: Ye Chen
Session: Poster Display session 1
Resources:
Abstract
4735 - Mutation profile of Tibetan lung cancer revealed by Whole Exome Sequencing
Presenter: Xin Wang
Session: Poster Display session 1
Resources:
Abstract
5236 - Synergistic activity between niraparib and chemotherapy in colorectal cancer: molecular determinants from a preclinical model
Presenter: Pietro Paolo Vitiello
Session: Poster Display session 1
Resources:
Abstract
4051 - cRGDfK (cRGD) conjugated Pyropheophor¬bide-a (Pyro), a new tumor photodynamic agent, is highly accumulated and specific in tumor cell killing
Presenter: Fengwei Wang
Session: Poster Display session 1
Resources:
Abstract
859 - The expression of MMR, CD133 and the presence of p53 wt predict the response to Cabazitaxel in malignant neural tumors cell lines.
Presenter: Kevin Doello
Session: Poster Display session 1
Resources:
Abstract
2497 - IKS01, a next generation antibody drug conjugate (ADC) designed to be efficacious in tumors with low and moderate levels of folate receptor expression
Presenter: Jenny Thirlway
Session: Poster Display session 1
Resources:
Abstract
1636 - Novel Non-Camptothecin Compounds with Antiproliferative Activities against Breast Cancer Cells
Presenter: Wen-shan Li
Session: Poster Display session 1
Resources:
Abstract
3443 - Sensitization of estrogen receptor-positive breast cancer cells to tamoxifen by novel epi-oligomycin A
Presenter: Margarita Yastrebova
Session: Poster Display session 1
Resources:
Abstract
840 - Autophagy inhibition enhances leflunomide-induced cytotoxicity in human bladder cancer cells
Presenter: Li Cheng
Session: Poster Display session 1
Resources:
Abstract
1735 - mTOR inhibition in the treatment of resistant breast cancer
Presenter: María Rodriguez
Session: Poster Display session 1
Resources:
Abstract